Analyst Consensus ?
ConsensusHold34 ratings
Bullish1441.2%
Neutral1544.1%
Bearish514.7%
ResMed Inc. · RMD · FY2027 Q1 · Calendar Q4 2026
ResMed reaffirms FY27 outlook as products and digital health support growth
The quarter supports a constructive operating case: resilient demand, product launches and digital-health adoption accompanied growth and margin expansion, while maintained guidance leaves execution and recall-related risks as the key tests.
Reported After market closeNYSEHealthcare
$35.56B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$2.91
Consensus $2.69
EPS surprise
+8.2%
Reported versus consensus
Reported revenue
$1.41B
Consensus $1.39B
Revenue surprise
+1.5%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
-9.1%
Event window
SPY move
-1.8%
Same window
Abnormal move
-7.3%
Stock minus SPY
Volume
3.1×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
RMDSPY benchmark
Ask FN2 about RMD FY2027 Q1
Transcript, numbers and history already loaded
Why did RMD fall 9.1% after beating EPS estimates in FY2027 Q1?What changed in RMD's guidance and outlook in FY2027 Q1?Give me the bull and bear case for RMD after FY2027 Q1 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Relative to the prior quarter, ResMed moved from a full-year FY2027 setup to an initial quarterly proof point: Q1 growth and margin expansion were reported, FY27 guidance was maintained, U.S. CPAP production began, and management emphasized additional products, digital-health expansion and the Astral phase-out.
Guidance delta
No change: FY27 guidance remains 5–7% core constant-currency revenue growth and $12–$12.25 EPS.
Key takeaways
- Q1 FY27 revenue grew 7% in constant currency and non-GAAP EPS grew 14%, according to the transcript analysis.
- Gross margin expanded 50 basis points, while management highlighted new devices, masks and myAir updates.
- Management reaffirmed FY27 guidance and reported more than $1 billion returned to shareholders.
Management priorities
- Expand U.S. manufacturing capacity and reduce supply-chain risk.
- Broaden the AirCurve, fabric-mask and myAir product platforms.
- Pursue aligned tuck-in acquisitions while phasing out Astral devices and supporting existing units.
Follow RMD with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$229.94Current
$175Low
$247.73Average
$345High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 31, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| RBC Capital | Outperform | Sector Perform | Upgrade | Sep 15, 2026 |
| Keybanc | Overweight | Overweight | Maintain | Aug 31, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Aug 7, 2026 |
| Piper Sandler | Neutral | Neutral | Maintain | Aug 7, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 15, 2026 |
| Citigroup | Neutral | Buy | Downgrade | Jul 13, 2026 |
| Jefferies | Hold | Hold | Maintain | Jul 10, 2026 |
| Morgan Stanley | Equal Weight | Overweight | Downgrade | Jun 17, 2026 |
| Stifel | Hold | Hold | Maintain | Jan 30, 2026 |
| Baird | Neutral | Outperform | Downgrade | Dec 16, 2025 |
| UBS | Buy | Buy | Maintain | Aug 1, 2025 |
| JP Morgan | Overweight | Overweight | Maintain | Apr 24, 2025 |
| Needham | Hold | Hold | Maintain | Jan 31, 2025 |
| B of A Securities | Buy | Buy | Maintain | Sep 26, 2024 |
| Wolfe Research | Underperform | Peer Perform | Downgrade | Sep 18, 2024 |
| Oppenheimer | Perform | Outperform | Downgrade | Jun 25, 2024 |
| CLSA | Buy | Outperform | Maintain | Jan 13, 2022 |
| Macquarie | Outperform | Neutral | Upgrade | Dec 6, 2021 |
| Goldman Sachs | Buy | Neutral | Upgrade | Jul 29, 2019 |
| Deutsche Bank | Buy | Hold | Upgrade | Mar 20, 2019 |
| BMO Capital | Outperform | Market Perform | Upgrade | Dec 10, 2018 |
| Barclays | Underweight | Underweight | Maintain | Oct 27, 2017 |
| Credit Suisse | Neutral | Outperform | Downgrade | Aug 2, 2017 |
| Bank of America | Neutral | Buy | Downgrade | Aug 2, 2017 |
| PiperJaffray | Neutral | Overweight | Downgrade | Apr 27, 2016 |
| BBY | Underperform | Underperform | Maintain | Feb 2, 2015 |
| Northland Securities | Underperform | Market Perform | Downgrade | May 27, 2014 |
| Northland Capital Markets | Underperform | Market Perform | Downgrade | May 27, 2014 |
| William Blair | Market Perform | Outperform | Downgrade | Jan 24, 2014 |
| Shaw Stockbroking | Buy | Buy | Maintain | Sep 20, 2013 |
| S&P Capital IQ | Buy | Buy | Maintain | Feb 26, 2013 |
| CBA | Buy | Hold | Upgrade | Aug 7, 2012 |
| Feltl & Co. | Hold | Hold | Maintain | Aug 6, 2012 |
| Bank oferica | Neutral | Neutral | Maintain | Apr 27, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $229.94. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Mizuho Securities | Anthony Petrone | $240 | $234.6 | +4.4% | Oct 13, 2026 |
| RBC Capital | Craig Wong-Pan | $262 | $222.99 | +13.9% | Sep 15, 2026 |
| KeyBanc | Analyst unavailable | $267 | $240.33 | +16.1% | Aug 31, 2026 |
| Redburn Partners | Analyst unavailable | $230 | $219.98 | +0.0% | Aug 19, 2026 |
| Robert W. Baird | Analyst unavailable | $213 | $212.38 | -7.4% | Aug 7, 2026 |
| KeyBanc | Analyst unavailable | $255 | $223.24 | +10.9% | Aug 7, 2026 |
| UBS | David Low | $300 | $195.97 | +30.5% | Jul 21, 2026 |
| RBC Capital | Analyst unavailable | $234 | $198.57 | +1.8% | Jul 16, 2026 |
| Mizuho Securities | Analyst unavailable | $220 | $193.01 | -4.3% | Jul 15, 2026 |
| Jefferies | Analyst unavailable | $225 | $204.5 | -2.1% | Jul 10, 2026 |
| RBC Capital | Analyst unavailable | $276 | $219.75 | +20.0% | Jul 8, 2026 |
| Wells Fargo | Analyst unavailable | $225 | $219.75 | -2.1% | Jul 8, 2026 |
| KeyBanc | Analyst unavailable | $266 | $188.63 | +15.7% | Jun 22, 2026 |
| Morgan Stanley | David Bailey | $230 | $193.94 | +0.0% | Jun 17, 2026 |
| Robert W. Baird | Analyst unavailable | $225 | $203.87 | -2.1% | May 1, 2026 |
| KeyBanc | Analyst unavailable | $290 | $219.85 | +26.1% | Apr 27, 2026 |
| Evercore ISI | Anthony Petrone | $255 | $228.33 | +10.9% | Apr 13, 2026 |
| RBC Capital | Craig Wong-Pan | $314 | $254.08 | +36.6% | Jan 30, 2026 |
| Stifel Nicolaus | Analyst unavailable | $265 | $257.61 | +15.2% | Jan 30, 2026 |
| KeyBanc | Brett Fishbin | $302 | $257.61 | +31.3% | Jan 30, 2026 |
| Robert W. Baird | Analyst unavailable | $281 | $257.61 | +22.2% | Jan 30, 2026 |
| Piper Sandler | Analyst unavailable | $275 | $257.61 | +19.6% | Jan 30, 2026 |
| Stifel Nicolaus | Jonathan Block | $260 | $245.94 | +13.1% | Dec 18, 2025 |
| Robert W. Baird | Analyst unavailable | $275 | $253.07 | +19.6% | Dec 16, 2025 |
| UBS | Marcus Curley | $345 | $251.38 | +50.0% | Dec 12, 2025 |
| Robert W. Baird | Analyst unavailable | $300 | $246.88 | +30.5% | Nov 3, 2025 |
| KeyBanc | Brett Fishbin | $299 | $244.12 | +30.0% | Oct 31, 2025 |
| Morgan Stanley | David Bailey | $305 | $252.26 | +32.6% | Oct 31, 2025 |
| Morgan Stanley | Analyst unavailable | $304 | $271.41 | +32.2% | Oct 21, 2025 |
| Wells Fargo | Analyst unavailable | $280 | $272 | +21.8% | Oct 13, 2025 |
| Morgan Stanley | David Bailey | $286 | $248.14 | +24.4% | May 20, 2025 |
| KeyBanc | Brett Fishbin | $274 | $232.65 | +19.2% | Apr 24, 2025 |
| Mizuho Securities | Anthony Petrone | $265 | $211.49 | +15.2% | Apr 16, 2025 |
| Stifel Nicolaus | Analyst unavailable | $240 | $223.83 | +4.4% | Mar 5, 2025 |
| Piper Sandler | Adam Maeder | $260 | $236.18 | +13.1% | Jan 31, 2025 |
| Stifel Nicolaus | Jonathan Block | $250 | $242.51 | +8.7% | Dec 12, 2024 |
| RBC Capital | Craig Wong-Pan | $224 | $238.95 | -2.6% | Oct 1, 2024 |
| Robert W. Baird | Joe Vruwink | $280 | $246.18 | +21.8% | Sep 23, 2024 |
| Wolfe Research | Mike Polark | $180 | $250.88 | -21.7% | Sep 18, 2024 |
| RBC Capital | Craig Wong-Pan | $187 | $194.27 | -18.7% | Apr 10, 2024 |
| Stifel Nicolaus | Mike Matson | $224 | $198.03 | -2.6% | Apr 1, 2024 |
| Oppenheimer | Suraj Kalia | $175 | $134.65 | -23.9% | Oct 27, 2023 |
| Needham | Mike Matson | $180 | $153.89 | -21.7% | Sep 6, 2023 |
| RBC Capital | Craig Wong-Pan | $244 | $197.57 | +6.1% | Jun 20, 2022 |
| RBC Capital | Analyst unavailable | $233 | $200.81 | +1.3% | Apr 29, 2022 |
| Oppenheimer | Suraj Kalia | $312 | $253.77 | +35.7% | Oct 14, 2021 |
| Morgan Stanley | Sean Laaman | $250 | $271.87 | +8.7% | Aug 4, 2021 |
| Jefferies | Anthony Petrone | $240 | $264.75 | +4.4% | Jul 28, 2021 |
Track every rating change on RMD the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationResMed Inc. is a leading global medical technology enterprise engaged in the creation, production, distribution, and marketing of healthcare devices and connected digital solutions. The company operates through two primary segments: Sleep and Respiratory Care, and Software as a Service. Its extensive product range addresses a variety of respiratory disorders, encompassing advanced medical and consumer technologies, ventilation devices, diagnostic equipment, mask systems for both clinical and personal use, headgear, and related accessories, alongside dental devices. ResMed also provides sophisticated cloud-based informatics to enhance patient management and operational efficiency.…
Historical context
All RMD earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| BTSG BrightSpring Health Services, Inc. Common Stock | FY2026 Q3 · Calendar Q4 2026 | — | +9.7% | BrightSpring posts broad Q3 growth while IRA pressure persists |
| ABBV AbbVie Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +1.2% | AbbVie Q3 2026: Guidance Raised as Immunology Drives Growth |
| BTSGU BrightSpring Health Services, Inc. Tangible Equity Unit | FY2026 Q3 · Calendar Q4 2026 | — | +9.9% | BrightSpring Q3: Pharmacy Growth Offsets IRA Pressure |
| REGN Regeneron Pharmaceuticals, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +12.3% | Regeneron: Core Brands Grow as Pipeline Milestones Advance |
| EXEL Exelixis, Inc. | FY2026 Q3 · Calendar Q4 2026 | +6.0% | +4.8% | Exelixis highlights zanzalintinib pipeline after strong Q3 |
| BBIO BridgeBio Pharma, Inc. | FY2026 Q3 · Calendar Q4 2026 | +22.5% | +6.0% | BridgeBio advances three launches while Attruby momentum holds |
Latest beats and misses
Who reports nextBeat on EPS
- WYFY2026 Q3 · October 29, 2026+128.3% EPS+3.0% move
- LNTFY2026 Q3 · October 29, 2026+16.0% EPS+1.4% move
- MTZFY2026 Q3 · October 29, 2026+0.3% EPS+0.8% move
- ERIEFY2026 Q3 · October 29, 2026+2.1% EPS+5.3% move
- IRFY2026 Q3 · October 29, 2026+18.5% EPS+0.2% move
- VLTOFY2026 Q3 · October 29, 2026+8.3% EPS+9.8% move
Get the RMD recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-10-30T14:14:36.352703+00:00
- FN2 earnings calendar · 2026-10-30T01:23:13.979536+00:00
- Polygon adjusted daily market bars · 2026-10-30T22:30:41.379698+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-30T22:30:41.376985+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-30. For educational purposes only; not investment advice.